Zenas BioPharma Statistics
Total Valuation
Zenas BioPharma has a market cap or net worth of $1.28 billion. The enterprise value is $937.29 million.
Important Dates
The last earnings date was Monday, March 16, 2026, before market open.
| Earnings Date | Mar 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Zenas BioPharma has 57.36 million shares outstanding. The number of shares has increased by 238.89% in one year.
| Current Share Class | 57.37M |
| Shares Outstanding | 57.36M |
| Shares Change (YoY) | +238.89% |
| Shares Change (QoQ) | +25.71% |
| Owned by Insiders (%) | 1.54% |
| Owned by Institutions (%) | 58.31% |
| Float | 34.50M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 127.92 |
| Forward PS | n/a |
| PB Ratio | 5.02 |
| P/TBV Ratio | 5.28 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 93.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.61, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.61 |
| Quick Ratio | 5.50 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -28.85 |
Financial Efficiency
Return on equity (ROE) is -136.22% and return on invested capital (ROIC) is -47.44%.
| Return on Equity (ROE) | -136.22% |
| Return on Assets (ROA) | -35.06% |
| Return on Invested Capital (ROIC) | -47.44% |
| Return on Capital Employed (ROCE) | -65.85% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $59,880 |
| Profits Per Employee | -$2.26M |
| Employee Count | 167 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -79,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +170.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +170.30% |
| 50-Day Moving Average | 22.89 |
| 200-Day Moving Average | 22.80 |
| Relative Strength Index (RSI) | 37.60 |
| Average Volume (20 Days) | 612,282 |
Short Selling Information
The latest short interest is 8.02 million, so 13.99% of the outstanding shares have been sold short.
| Short Interest | 8.02M |
| Short Previous Month | 7.80M |
| Short % of Shares Out | 13.99% |
| Short % of Float | 23.26% |
| Short Ratio (days to cover) | 9.98 |
Income Statement
In the last 12 months, Zenas BioPharma had revenue of $10.00 million and -$377.74 million in losses. Loss per share was -$8.44.
| Revenue | 10.00M |
| Gross Profit | 10.00M |
| Operating Income | -211.39M |
| Pretax Income | -377.82M |
| Net Income | -377.74M |
| EBITDA | -211.33M |
| EBIT | -211.39M |
| Loss Per Share | -$8.44 |
Full Income StatementBalance Sheet
The company has $343.19 million in cash and $1.33 million in debt, with a net cash position of $341.87 million or $5.96 per share.
| Cash & Cash Equivalents | 343.19M |
| Total Debt | 1.33M |
| Net Cash | 341.87M |
| Net Cash Per Share | $5.96 |
| Equity (Book Value) | 242.14M |
| Book Value Per Share | 4.44 |
| Working Capital | 288.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$172.33 million and capital expenditures -$18,000, giving a free cash flow of -$172.35 million.
| Operating Cash Flow | -172.33M |
| Capital Expenditures | -18,000 |
| Depreciation & Amortization | 56,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -172.35M |
| FCF Per Share | -$3.00 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -2,113.85% |
| Pretax Margin | -3,778.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zenas BioPharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -238.89% |
| Shareholder Yield | -238.89% |
| Earnings Yield | -29.53% |
| FCF Yield | -13.47% |
Analyst Forecast
The average price target for Zenas BioPharma is $42.14, which is 88.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $42.14 |
| Price Target Difference | 88.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 115.10% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Zenas BioPharma has an Altman Z-Score of -0.33 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.33 |
| Piotroski F-Score | 2 |
